课题基金 / 基金详情

Application of Intelligent Targeting System for Cancer Gene Therapy

Application of Intelligent Targeting System for Cancer Gene Therapy
智能靶向系统在癌症基因治疗中的应用
批准号:
10470254
负责人:
YANAGIE Hironobu
金额:
$8.06万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B).
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2000

项目摘要

项目成果

YANAGIE Hironobu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1) Application of boron entrapped stealth liposome to tumour cell growth inhibition in in vivo boron neutron capture therapy model : The tumor cell destruction in boron neutron-capture therapy (BNCT) is due to the nuclear reaction between ^<10>B and thermal neutrons. It is necessary for effective BNCT to accumulate of ^<10>B atoms in the tumor cells. We prepare a polyethylene-glycol (PEG) binding liposome (DPPC/cholesterol/DSPC-PEG2000) entrapped ^<10>B compound for the delivery system. We evaluated the cytotoxic effects of intrveneously injected ^<10>B-PEG-liposome on human pancreatic carcinoma xenografts in nude mice with thermal neutron irradiation. After thermal neutron irradiation of mice injected with ^<10>B- bare liposome or ^<10>B-PEG-liposome, AsPC-1 tumour growth was suppressed relative to controls. Injection of ^<10>B-PEG-liposome caused the greatest tumour suppression with thermal neutron irradiation in vivo These results suggest that intraveneous injection of ^<10>B-PEG-li … More posome can increase the retention of ^<10>B atoms by tumor cells, causing tumor growth suppression in vivo upon thermal neutron irradiation.2) Liposomal gene delivery using novel lipoplexes called "Qplex" for cancer therapy in vitro : Non-viral vectors, such as cationic liposomes and cationic polymers have developed in the merits without immunogenicity, potential recombination, nor complementation. It is necessary to increase the transfectional efficiency when we use non-viral vector on cancer gene therapy. We have prepared new typed plasmid DNA-cationic lipoplexes, called quatenary complex ("Qplex"), and evaluated DNA delivery efficiency. Qplex is composed with cationic liposome, pDNA, protamine and transferrin. The lipid of liposome M-(α-trimethylammonioacetyl)-didodecyl-D-glutamatechloride (TMAG)/dilauroyl-phospatidylcholine (DLPC)/dioleoylphospatidylethanolamine (DOPE) (1 : 2 : 2). The transfectional efficiency of lac Z gene is increased to 67% with Qplex from 4% with conventional cationic lipoplexes in Xgal staining. The transfection efficiency is superior in the existence of serum.Tob (Transducer of Erb B-2) is a newly identified tumor suppressor that may interact and interfere with tyrosine kinase receptors including Erb B-2. Introduction of tob gene into NIH3T3 cells results in suppression of growth of the cells. Tob plasmid was entrapped into the "Qplex". The tumor growth suppression of AsPC-1 pancreatic cancer cells was shown in 50% of thymidine uptake regression. These results, suggest that the Qplex has an candidate for non viral vector of gene therapy for treatment of cancer.3) Transfection with Luciferase Plasmid/Chitosan Complex and Analyses of Transfection Mechanism : In this study, we transfected tumor cells (A549, B16 and Hela) with the plasmid/chitosan complex. The complex showed higher transfection activity than the plasmid/lipofectin complex did. Although the polygalactosamine is the same amino polysaccharide as the chitosan, the plasmid/polygalactosamine complex did not show any gene expression. So we analysed the travsfection mechanism between chitosan and polygalactosamine complex. We synthesized FITC-labeled luciferase plasmid and Texas Redlabeled chitosan to evaluate the transfection efficiency, cell uptake and sub-cellular distribution of the plasmid/chitosan complex. Gel shift assay was used to evaluate the stability of the complexes in the presence of Dnase I and anionic surfactant.. Less
期刊论文(86)
专著(0)
科研奖励(0)
会议论文
T.Sato et al: "Quantitative measurement of the interaction between ganglioside monolayers and wheat germ agglutinin (WGA) by a guartzcrystal microbalance."Biochim.Biophys.Acta.. 1380. 82-92 (1998)
T.Sato 等人:“通过石英晶体微天平定量测量神经节苷脂单层和麦芽凝集素 (WGA) 之间的相互作用。”Biochim.Biophys.Acta.. 1380. 82-92 (1998)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yanagie et al.: "Inhibition of human pancreatic cancer growth by the liposomal delivery of a novel growth suppressing gene "tob" in vitro"Reseach in Experimental Medicine. (on press).
Yanagie 等人:“在体外通过脂质体递送新型生长抑制基因“tob”来抑制人类胰腺癌生长”实验医学研究。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
K.Kono,H.Yanagie et al: "Novel gene delivery systems : complexes of fusogenic polymer-modified liposomes and lipoplexes"Gene Therapy. (in press). (2000)
K.Kono、H.Yanagie 等人:“新型基因传递系统:融合聚合物修饰的脂质体和脂质复合物的复合物”基因治疗。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
H.Yanagie, et al: "Inhibition of human pancreatic cancer growth by the adenovirus-mediated introduction of a novel growth suppressing gene, tob, in vitro."In P.Walden et al (eds) ; Gene Therapy of Cancer. Plenum Press, New York. 91-96 (1998)
H.Yanagie 等人:“在体外通过腺病毒介导的新型生长抑制基因 tob 的引入来抑制人类胰腺癌的生长。”P.Walden 等人(编);
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
37
    Development of Intelligent Gadorinium Neutron Capture Therapy asCancer Specific Atomic Suppression Therapy
    • 批准号:
      23659639
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      YANAGIE Hironobu
    • 依托单位:
    Development of Gene Therapy with Nanotechnology derived Intelligent Drug Deliver Systems
    • 批准号:
      15390389
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.47万
    • 财政年份:
      2003
    • 负责人:
      YANAGIE Hironobu
    • 依托单位:
    Molecular Targeting Therapy with Intelligent Drug Delivery System using Transporter
    • 批准号:
      13557104
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.96万
    • 财政年份:
      2001
    • 负责人:
      YANAGIE Hironobu
    • 依托单位:
    Development of New Strategy of Boron Neutron Capture Therapy to Cancer Combined with Tumor Specific Gene Delivery
    海外基金